In a phase I trial (FANG vaccine trial), an autologous tumor-based product incorporating a plasmid encoding GM-CSF and a bifunctional short hairpin RNAi (bi-shRNAi) targeting Furin was recently found to be beneficial with 91% success rate in patients with advanced cancer [35]. The gene discussed is CSF2; the disease is neoplasm.